Observations placeholder
Rasilez
Identifier
019994
Type of Spiritual Experience
Background
A description of the experience
Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is a direct renin inhibitor. Its current licensed indication is essential (primary) hypertension. While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit. [sic]
In December 2011, Novartis halted a clinical trial of the drug after discovering increased incidence of nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney impairment.
Adverse effects
- Angioedema
- High blood potassium level (particularly when used with ACE inhibitors in diabetic patients)
- Low blood pressure (particularly in volume-depleted patients)
- Diarrhea and other GI symptoms
- Headache
- Dizziness
- Cough
- Rash
- Elevated uric acid, gout, and kidney stones
On Jan, 09, 2017 5,010 people reported to have side effects when taking Rasilez.
Among them, 19 people (0.38%) have Hallucination
Time on Rasilez when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 66.67% | 33.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Jan, 30, 2016: 4,117 people reported to have side effects when taking Rasilez. Among them, 154 people (3.74%) have Death.
Time on Rasilez when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 8.33% | 33.33% | 25.00% | 8.33% | 25.00% | 0.00% | 0.00% |